Recent years have marked exceptional scientific breakthroughs in our understanding of inherited susceptibility to breast cancer, with the identifications of the BRCA1 and BRCA2 genes. Inherited mutation of one of these genes make their carriers at a much increased risk of developing breast as well as ovarian cancer. It has become possible, and increasingly common, to test for the presence of these genes. While the availability of testing represents a major opportunity both scientifically and clinically, it also creates important challenges for women facing the testing decision and for their physicians and genetic counselors. The chance of carrying a genetic mutation caries markedly from women to woman, depending on family history of breast and related cancers. As a result, increasing attention needs to be given to understanding and conveying risk information in an individualized way. Evidence is emerging that the simple rules that provided important initial guidance in this process are not fully adequate, and that computer-based risk prediction algorithms that fully explicitate our knowledge about the nature of the inheritance mechanism can contribute importantly to a woman's decision. In the first phase of the proposed research we will further develop a computer-based risk prediction algorithms for determining the probability that an individual is a carrier of a mutation of the BRCA1 and BRCA2 genes based on a detailed description of his or her family history. In the second phase of the proposed research we will validating the model using data arising in high risk clinics, that is in the same conditions as those of the intended use of the model. In view of the national shortage of trained genetic counselors, and the great public interest in and awareness of genetic testing, findings from our study will make a significant contribution to understanding and promoting informed decision-making about genetic testing for susceptibility to breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA068438-05S2
Application #
6664500
Study Section
Project Start
1999-09-01
Project End
2003-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2002
Total Cost
$179,222
Indirect Cost
Name
Duke University
Department
Type
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications